Skip to Content

Toviaz Approval History

FDA Approved: Yes (First approved October 31, 2008)
Brand name: Toviaz
Generic name: fesoterodine fumarate
Dosage form: Extended Release Tablets
Company: Pfizer Inc.
Treatment for: Overactive Bladder

Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Development History and FDA Approval Process for Toviaz

DateArticle
Oct 31, 2008Approval Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide